Imagenebio Inc IMA

$4.15 -0.09 (-2.11%)

Valuation

Market cap
48,128,000
Revenue TTM
$800,000
Net income TTM
$-45,350,000
PE ratio
0.00
Forward PE
—
Profit margin
-5,668.75%
Debt to equity
0.00

Trading

Volume
20,700
Avg volume
14,166
Day's range
$4.14 – $4.20
Shares out
11,351,000
Stochastic %K
30%
Beta
0.74
Analysts
Sell
Price target
$18.00

Price

Company profile

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Onco...

Show more

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
858 345 6265
Website
https://www.inmagenebio.com
Address
12526 High Bluff Drive, Suite 345, San Diego, United States

Latest news

Stocktwits

J7263 Sep 9, 12:19 AM
$IMA continues to age well 🤣
0 replies
SybilDorsett Aug 21, 1:26 PM
$IMA COVERAGE INITIATED: ImageneBio (IMA) initiated by H.C. Wainwright. Initial rating Buy. 8:40 AM ET 8/21/2026
0 replies
J7263 Aug 12, 3:36 AM
$IMA still a stick in the mud.
0 replies
_DannyGh8st Jul 26, 2:28 PM
$IMA Insurance brokerage growth: Benefits from rising demand for commercial insurance and risk management✅
0 replies
SuperGreenToday Jun 18, 7:12 PM
$IMA
0 replies
J7263 May 29, 8:25 PM
$IMA stick in the mud. That opportunity cost 😬
0 replies
NVDAMillionaire May 19, 7:40 PM
$IMA Outstanding article that hits the mark on IMA's current state. So if you want to refresh your IMA insights or learn about IMA from scratch, this is a must read. https://everyticker.com/quote/IMA/analysis/imagenebio-s-single-asset-gamble-can-a-safer-ox40-inhibitor-justify-the-risk-nasdaq-ima
0 replies
BecauseOfScout Apr 30, 4:41 PM
$IMA Can’t ignore the 18m vol hammer candle. Small stater started.
0 replies